Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
Hao Su,1,* Xiao Shang,1,* Hongruo Liu,2 Yutong Wang,1 Yang Yu,3 Yanhua Xu,4 Kui Jiang,2,* Fengzhi Feng1,* 1Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Chine...
Saved in:
| Main Authors: | Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-02-01
|
| Series: | International Journal of Women's Health |
| Subjects: | |
| Online Access: | https://www.dovepress.com/efficacy-and-safety-of-low-dose-lenvatinib-and-toripalimab-in-patients-peer-reviewed-fulltext-article-IJWH |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response
by: Guanlin Dai, et al.
Published: (2025-08-01) -
Emerging Role of Lenvatinib in Treating Platinum-Refractory Head and Neck Cancer in Resource-Limited Settings
by: Avinash Khadela, et al. -
The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors
by: Baoyue Pan, et al.
Published: (2025-08-01) -
Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study
by: Alexandra R. Steck, et al.
Published: (2025-08-01) -
Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study
by: Tamaki Tanaka, et al.
Published: (2025-06-01)